{"contentid": 488430, "importid": NaN, "name": "Biogen beats expectations, despite 24% sales dive", "introduction": "US biotech major Biogen today reported first quarter 2021 financial results which, though well below 2020 comparisons, beat analysts\u00e2\u0080\u0099 expectations.", "content": "<p>US biotech major Biogen (Nasdaq: BIIB) today reported first quarter 2021 financial results which, though well below 2020 comparisons, beat analysts&rsquo; expectations. The news saw the company&rsquo;s share rise 1.4% pre-market, but they were down 4.1% at $259.84 mid-morning.</p>\n<p>First quarter total revenue of $2,694 million decreased 24% versus the prior year at actual currency and decreased 25% at constant currency.</p>\n<p>First quarter generally accepted accounting principles (GAAP) net income and diluted earnings per share (EPS) attributable to Biogen were $410 million and $2.69, respectively, compared to $1.4 billion, or $8.10 per share, in the like quarter in 2020. First quarter Non-GAAP net income and diluted EPS attributable to Biogen were $813 million and $5.34, respectively.</p>\n<p>Analysts polled by FactSet expected Biogen earnings to be $4.97 per share and revenues $2.65 billion.</p>\n<h2><strong>Full-year guidance</strong></h2>\n<p>For the year, Biogen guided to adjusted earnings of $17.50-$19 per share on $10.45 billion to $10.75 billion in sales. Analysts are calling for adjusted profit of $18.33 a share and $10.5 billion in sales.</p>\n<p>&ldquo;Our first quarter 2021 results were consistent with our expectations across MS, SMA, and biosimilars despite increased competition,&rdquo; said Michel Vounatsos, Biogen&rsquo;s chief executive, adding: &ldquo;The launch of Vumerity [diroximel fumarate] has continued to accelerate, providing a valuable new option for patients, and we continue to diligently manage operating expenses. We are pleased with our operational performance during the quarter, and we are increasing our earnings guidance for the full year.&rdquo;</p>\n<p>&ldquo;With an anticipated regulatory decision for [Alzheimer&rsquo;s candidate] aducanumab in the US and a number of exciting pivotal readouts expected this year in depression, choroideremia, and ALS, we continue to believe that 2021 will be a transformative year for Biogen,&rdquo; Mr Vounatsos said.</p>\n<h2><strong>Product sales &ndash; 1<sup>st</sup> quarter 2021</strong></h2>\n<p>Multiple sclerosis (MS) revenue, including $209 million royalties on sales of Ocrevus (ocrelizumab), totaled $1,693 million, a decrease of 26% versus the prior year at both actual and constant currency. Tysabri (natalizumab) sales were $503 million, down 4%.</p>\n<p>MS therapy Tecfidera (diroximel fumarate) generated $479.3 million in revenue for the quarter, down from $1.1 billion in the same quarter last year.&nbsp;</p>\n<p>Spinal muscular atrophy drug Spinraza (nusinersen) revenue of $521 million decreased 8% versus the prior year at actual currency and decreased 12% at constant currency</p>\n<p>Avonex (interferon beta-1a) sales were $311.1 million, a decrease of 5%.</p>\n<p>Biosimilars revenue of $205 million decreased 6% versus the prior year at actual currency and decreased 13% at constant currency.</p>", "date": "2021-04-22 16:19:00", "meta_title": "Biogen beats expectations, despite 24% sales dive", "meta_keywords": "Biogen, Financial results, First-quarter, 2021. Ocrevus, Tysabri, Tecfidra, Spinraza", "meta_description": "Biogen beats expectations, despite 24% sales dive", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-22 16:17:07", "updated": "2021-04-22 16:27:58", "access": NaN, "url": "https://www.thepharmaletter.com/article/biogen-beats-expectations-despite-24-sales-dive", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "biogen_large.jpg", "image2id": "biogen_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Musculoskeletal, Neurological, Rare diseases", "topic_tag": "Financial", "geography_tag": "USA", "company_tag": "Biogen", "drug_tag": "Avonex, Ocrevus, Spinraza, Tecfidera, Tysabri", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-22 16:19:00"}